Brought together by conjugation: CMC Biologics A/S and IDT Biologika form ADC pact
The collaboration - financial terms of which were not disclosed – will see CMC provide process development and bulk antibody manufacturing services, while IDT will focus on conjugating the drug warheads to the antibodies. IDT will also handle fill finish and packaging.
The aim is to provide drug industry customers with a faster means of making ADC for clinical trials and commercial launch.
IDT CEO Ralf Pfirmann said: "The collaboration with CMC Biologics is an important step to provide full ADC manufacturing services to meet the needs of ADC development and production in this rapidly growing field."
This was echoed by CMC CEO, Gustavo Mahler, who said: "We are delighted to be working with IDT Biologika, one of the fastest growing and innovative CMOs in Germany and now in North America.”
The deal comes a few months after IDT has opened its first facility in the US. The vaccine manufacturing site in Rockville, Maryland provides process development, cell banking, cGMP manufacturing, purification and formulation, and fill/finish services.
IDT bought the facility last June from Aeras, which is a non-profit research company focused on tuberculosis vaccine development.
